Monte Rosa Therapeutics, Inc. GLUE Change in receivables
Change in receivables at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s change in receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s change in receivables?
- Monte Rosa Therapeutics, Inc. (GLUE) reported change in receivables of $9K in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s change in receivables changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s change in receivables decreased by 99.3% year-over-year, from $1.24M to $9K.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s change in receivables?
- Over 2 years (2022 to 2025), Monte Rosa Therapeutics, Inc.'s change in receivables has grown at a 406.2% compound annual growth rate (CAGR), from $187K to $4.79M.
- What does change in receivables mean?
- Change in total receivables including trade and non-trade receivables.